Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "March"

845 News Found

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
News | August 06, 2024

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr

Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024


Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr
News | August 06, 2024

Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr

Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024


Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
News | August 06, 2024

Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr

Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024


Cupid post Q1 FY25 profit at Rs. 8.25 Cr
News | August 06, 2024

Cupid post Q1 FY25 profit at Rs. 8.25 Cr

Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024


Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
News | August 05, 2024

Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr

Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024


European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion
Drug Approval | August 03, 2024

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept


Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
Drug Approval | August 03, 2024

Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL

Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia


Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
News | August 02, 2024

Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024


Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr
News | August 01, 2024

Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr

Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024